UGN-102 Improves Survival, Elicits CRs in Low-Grade, Intermediate-Risk NMIBC

Treatment with UGN-102 with or without transurethral resection of bladder tumors led to an improvement in disease-free survival compared with TURBT alone in patients with low-grade, intermediate-risk non–muscle-invasive bladder cancer.

Related Keywords

Israel ,United States ,New Jersey ,Urogen Pharma ,Sandip Prasad ,Liz Barrett ,Genitourinary Surgical Oncology ,Morristown Medical ,Atlantic Health System ,Urothelial Cancer ,Non Muscle Invasive Bladder Cancer ,Ugn 102 Mitomycin ,Transurethral Resection ,Phase 3 Atlas Trial ,Nct04688931 ,Phase 3 Envision Trial ,Nct05243550 ,